NRE 8011/8012 Seminar


Local Collaborations in Future QUANTEC and HyTEC style Outcomes Studies


Dr. Jimm Grimm


Wellstar Health System


Thursday, March 7, 2024 at 11:00:00 AM   


Boggs Building, Room 3-47


Dr. Fan Zhang


This presentation will overview radiation dose response from Rubin, Emami, QUANTEC, HyTEC and upcoming studies, with a focus on how institutions can collaborate locally. For example, a similar project on reirradiation is beginning and this will provide opportunities for involvement from multiple institutions within our region: Clinical need and utilization of reirradiation are increasing rapidly in the international radiation oncology community but the therapeutic index in this new paradigm is poorly understood due to the complex and multifaceted nature of the current treatment process, and due to the limited reporting of details in the published data. Numerous clinical reports have been published on reirradiation, focusing on tissue tolerance, cumulative dose and dose distribution, but the time recovery factors for organs at risk are not yet well quantified and the data severely lack detail. As such, a large scale collaborative project is needed, like the recently completed HyTEC project, which was initially conceived out of the need for detailed data to construct TCP and NTCP models for SBRT. About 90% of the existing NTCP models for SBRT were published during the HyTEC project itself, showing that sparsity of data should not be the reason to prevent the project; sparsity of solid data is the very reason that the proposed Reirradiation Treatment Effects in the Clinic (ReTEC) project is necessary and timely. This presentation will show the practical initial steps that are being taken to begin the reirradiation study.


Dr. Jimm Grimm, PhD, is a clinical physicist who analyzes radiation dose response. He has commissioned several CyberKnife systems and provided physics support for thousands of Stereotactic Ablative Body Radiotherapy (SABR) Stereotactic Body Radiation Therapy (SBRT) cases. Dr. Grimm designed the DVH Evaluator, an FDA cleared software tool that aids with comparing radiation therapy treatment plans to applicable dose tolerance limits, and for recording follow-up patient response and symptoms. The software has been used in the statistical tumor control probability (TCP) and normal tissue complication probability (NTCP) dose-response modeling of data from more than 30,000 SBRT cases for several published clinical datasets including the full April 2016 issue of Seminars in Radiation Oncology on NTCP for SBRT, as well as the May 2021 Special Issue of the Red Journal on HyTEC: High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic. Dr. Grimm is very appreciative of the more than 100 experts and authors who made these works possible.


Meet the speaker